Author

Jan Sus

Observed name: J. Sus

Institution: AOP Orphan (Austria)

Observed institutions: AOP Orphan (Austria), Amgen (United Kingdom)

ORCID: 0009-0003-9832-6526

Observed ORCID: 0009-0003-9832-6526

OpenAlex ID: A5083280695

Landiolol for heart rate control in patients with septic shock and persistent tachycardia. A multicenter randomized clinical trial (Landi-SEP)

2024 · Sebastian Rehberg, Sandra Frank, et al. · Intensive Care Medicine · 77

A multicentre observational study on landiolol use, efficacy, and safety in European patients with supraventricular arrhythmia (Landi-UP)

2025 · Al-Medina Dizdarevic, Marek Šramko, et al. · European Heart Journal Acute Cardiovascular Care · 4

Abstract 8440: Effectiveness of Intravenous Landiolol for Acute Management of Pediatric Supraventricular Tachycardia: Post-Hoc Analysis of LANDI-PED Trial

2026 · Anna Stroble, Jan Sus, et al. · Circulation

Pharmacokinetics of Landiolol and Its Metabolite M1 During Renal Replacement Therapy in Septic Shock Patients: A Sub-Study of the Landi-SEP Trial

2026 · Sebastian Rehberg, Rainer Borgstedt, et al. · European Journal of Drug Metabolism and Pharmacokinetics

HTA19 Insights Into NICE Technology Appraisal Outcomes in Oncology

2023 · S. Champsi, D. Howard, et al. · Value in Health

Works count: 5

Citation count: 81

H-index: 2

I10-index: 1